Novogene, a leading global genomics sequencing provider, announced today that it has installed its first Illumina NovaSeq™ X Plus system at their UK site in the Cambridge Science Park. This is one of four units to be installed in Novogene’s labs across Europe, Asia and the USA.

As a trusted worldwide genomics partner, Novogene aim to empower the scientific community with more efficient, cost effective and sustainable sequencing to help drive their ground-breaking research. Illumina’s NovaSeq X Sequencing System sets a new benchmark for high-throughput sequencing — providing exceptional accuracy for data-intensive applications and unprecedented throughput at scale. With a throughput of up to 2.5 times that of prior sequencers (with maximum 16Tb output in 48 hours) and the ability to generate more than 20,000 whole genomes per year, the NovaSeq X series is one of the most powerful ultra-high-throughput sequencers available.

“The field of genomics has seen remarkable progress over the past decade, driven by the introduction of more powerful, faster, and cost-effective NGS platforms. With the current trend of new NGS sequencers leaning towards ultra-high throughput and increased workflow automation, we foresee that the future of genomic sequencing will increasingly gravitate towards an outsourced, centralised service model. Novogene has been a global leader in democratizing access to high-quality and cost effective NGS services worldwide. This is reaffirmed in our commitment to rolling out the latest Illumina sequencing machines.” said Dr. Ruiqiang Li, Founder and President of Novogene.

Novogene operates seven NGS laboratories globally and sequences over two million samples every year in collaboration with 6,000+ institutions and businesses. With a focus on innovation, speed, scale, accuracy, and sustainability, Novogene has contributed to 16,000+ SCI publications with a cumulative impact factor of 100,000+. With its commitment to serving the global scientific community with the best tools and services available, Novogene is well-positioned to continue its leadership in the genomics industry.